The State University of New York

Anika Research, Inc.

Other

The General Hospital Corporation

Medchem Products, Inc.

Massachusetts General Hospital Corporation

Anika Therapeutics, Inc.

David A Swann

Glenn D Prestwich

Jing-Wen Kuo

Patricia K Donahoe

Gerald P Budzik

Jing-wen Kuo

Bernard P Sullivan

Vladimir Pinsky

David Bruce Miller

Dale P DeVore

William D Richards

Gordon Jamieson

Kenneth R Richardson

Tarlach Singh

Ariel Ferdman

This invention describes a method for preparing water-insoluble biocompatible gels, films and sponges by reacting hyaluronic acid, or a salt thereof, with a carbodiimide in the absence of a nucleophile or a polyanionic polysaccharide. The water-insoluble gels, films and sponges of this invention may be used as surgical aids to prevent adhesions of body tissues and as drug delivery vehicles.

Water-insoluble derivatives of hyaluronic acid crosslinked with a biscarbodiimide

Method for treating wounds using modified hyaluronic acid crosslinked

Water-insoluble derivatives of hyaluronic acid and their methods of

A method for sterilizing solid hyaluronic acid includes autoclaving solid hyaluronic acid, whereby the solid hyaluronic acid is exposed to saturated steam at positive gauge pressure for a period of time that is sufficient to sterilize the solid hyaluronic acid. In one embodiment, autoclaving includes exposing the solid hyaluronic acid to saturated steam at a gauge pressure of about one atmosphere for a period of time between about fifteen and thirty minutes.

Steam-sterilizing solid hyaluronic acid

A method of treating a wound site wherein a porous, adhesive backed dressing is utilized. A vacuum and/or heat is applied to the wound site through the dressing so as to draw the tissue adjacent the wound site to the dressing so as to minimize trauma to the wound and increase the adherence of the adhesive.

Method and device for wound closure

Purified Mullerian inhibiting substance (MIS) is obtained from testicular tissue by extraction, density gradient sedimentation and chromatography. The purified MIS has selective activity for inhibiting the growth of human ovarian cancer cells.

Purified Mullerian inhibiting substance and process for treating human

Solutions of sodium hyaluronate in physiological saline with a kinematic viscosity of from 45,000 to 64,000 cSt. are found to effect a smaller increase in post-operative intra-ocular pressure following use as an aid in opthalmological surgery, when the weight average molecular weight of the hyaluronate is within the range of from 1 to 2 million Daltons.

Sodium hyaluronate composition

Improved overall yields of hyaluronic acid are obtained by controlling the oxygen available for metabolism by a hyaluronic acid producing microorganism. Relatively high oxygen concentrations are made available during the initial exponential growth phase of the cultivated microorganism, until a predetermined growth has been reached. At this time, the available oxygen is limited to stimulate a disproportionately larger production of the desired hyaluronic acid.

Biosynthesis of hyaluronic acid

A process for purifying Mullerian Inhibiting Substance (MIS) from testicular tissue which comprises incubating testicular tissue in a culture media in the presence of a protease inhibitor in order to extract MIS from the tissue, chromatographing the extract on an anionic exchange resin followed by chromatographing the biologically active product obtained therefrom on a cationic exchange resin; the biologically active material from the cationic exchange resin is chromatographed by lectin affinity chromatography on wheat germ lectin and then either chromatographed by lectin affinity chromatography on concanavalin A or by triazinyl dye affinity chromatography on a appropriate triazinyl dye; MIS is obtained in 8,000-fold and 15,000-fold purification over original testicular tissue.

Purified Mullerian Inhibiting Substance and method of use

A process for purifying Mullerian Inhibiting Substance (MIS) from testicular tissue which comprises incubating testicular tissue in a culture media in the presence of a protease inhibitor in order to extract MIS from the tissue, chromatographing the extract on an anionic exchange resin followed by chromatographing the biologically active product obtained therefrom on a cationic exchange resin; the biologically active material from the cationic exchange resin is chromatographed by lectin affinity chromatography on wheat germ lectin and then either chromatographed by lectin affinity chromatography on concanavalin A or by triazinyl dye affinity chromatography on an appropriate triazinyl dye; MIS is obtained in 8,000-fold and 15,000-fold purification over original testicular tissue.

Purified Mullerian Inhibiting Substance and method of purification

Growing community of inventors

Lexington, MA, United States of America

David A Swann